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Tuberculous pleurisy results from tuberculous infection of the pleura, the membrane 
surrounding the lungs. This results in a build up of 'fluid around the lung which impairs 
breathing and may also lead to long term effects permanently restricting lung function. 
Some clinicians believe that steroids used in combination with anti-tuberculous drugs can 
help to prevent these complications. Concern also exists regarding the potential adverse 
effects of steroids, especially in HIV positive patients. However, high quality evidence on 
the benefits and harms associated with steroid use is limited. 
This review finds no clear evidence on which to base decisions regarding the use of 
steroids in patients with tuberculous pleurisy. Trials that are large enough to assess 
important outcomes such as lung function and death are needed. Future research 




Background: Corticosteroids used in addition to anti-tuberculous therapy have been 
reported to benefit people with tuberculous pleurisy. However, research findings are not 
consistent, raising doubt as to whether such treatment is worthwhile. Concem also exists 
regarding the potential adverse effects of steroids, especially in HIV positive patients. An 
earlier Cochrane review summarized the existing evidence on the effects of steroids in 
people with tuberculous pleurisy. This review updates the evidence and, for the first time 
sheds light on the effects of steroids in patients with tuberculous pleurisy co-infected with 
HIV. 
Objectives: To examine the evidence from randomised controlled tri~ls conceming the 
effect of steroids in patients with tuberculosis of the pleura. 
Search strategy: The following databases were searched: Cochrane Infectious 
Diseases Group specialized trials register (October 2003), The Cochrane Central 
Register of Controlled Trials (The Cochrane Library Issue 3, 2003), MEDLINE (1966 to 
October 2003), EMBASE (1980 to October 2003), LILACS (October 2003), U.S. NIH 
ClinicalTrials.gov (October 2003), and Current Controlled Trials (October 2003). In 
addition, Lists of references from review articles and primary studies were scanned for 
further studies 
Selection criteria: Randomised and quasi-randomised trials evaluating the effects of 
adjunctive corticosteroids in patients diagnosed with TB pleurisy were sought. 
Data collection & analysis: Two authors independently applied inclusion criteria, 
v 
assessed trial quality and extracted relevant information. We analyzed data using 
Review Manager (Version 4.2) and pooled estimates of effect using relative risks for 
binary data. 
Main results: Four trials with 433 participants met the inclusion criteria; only one study 
included patients with HIV infection. 
Compared to placebo, steroid use was associated with less residual pleural fluid at both 4 
weeks (2 trials, 311 participants: relative risk (RR) 0.67, 95% confidence interval (CI) 
0.50 to 0.90) and 8 weeks (2 trials, 234 patients: RR 0.53, 95% CI 0.37 to 0.77). 
However, we found no evidence of an effect of steroids on respiratory function, mortality, 
pleural thickening or pleural adhesions. 
Although discontinuation of treatment due to adverse effects was more frequent in 
patients receiving steroids than placebo, (3 trials, 304 participants: RR = 2.67, 95% CI 
1.03 to 6.96) the effects were generally mild. It is possible that the risk of Kaposi 
sarcoma is increased in HIV positive patients receiving steroids (1 trial, 194 participants: 
RR = 13.00, 95% CI 0.74 to 227.63). 
Conclusions: There are currently insufficient data to support evidence-based 
recommendations regarding the use of adjunctive steroids in patients with tuberculous 
pleurisy. Randomised trials that are sufficiently powered to evaluate both morbidity and 
mortality are needed. In people co-infected with HIV the effects of steroids on HIV-
related complications, such as Kaposi sarcoma, should be assessed. 
vi 
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Extrapulmonary tuberculosis including tuberculous lymphadenitis, pericarditis, meningitis 
and pleural effusion has become more frequent in recent years (Harries 1990) and this 
increase is believed to be attributable to co-infection with HIV (Song 2003; Yang 2004). 
1.1 Definition and Incidence 
Tuberculous pleural effusion (TPE) arises from abnormal accumulation of fluid in the 
pleural space between the lungs and chest wall. It is thought to be a delayed 
hypersensitivity reaction following a recent mycobacterial infection of the pleura, a semi-
permeable membrane covering the lungs (Rossi 1987). TPE is the most frequent 
extrapulmonary manifestation of TB (Mehta 1991) and is relatively common in areas 
where TB occurs. In one series of 1700 TB patients, 70 cases of TPE were identified 
(Seibert 1991). A higher prevalence of TPE has been reported in HIV infected 
participants than in those not infected with the virus (Elliott 1990; Frye 1997). Possible 
explanations for this association include a higher burden of microorganisms due to 
impaired host response (Relkin 1994) and detection bias resulting from more opportunity 
for diagnosis ofTPE in HIV positive individuals (Frye 1997). 
1.2 Prognosis 
The clinical manifestation of TPE is acute with symptoms including cough, fever, chest 
pain and dyspnoea (Morehead 1998). Although TPE can resolve spontaneously within a 
few weeks or months, medical treatment is believed to speed resolution of the effusion 
and reduce long-term complications such as fibrosis and thickening of the pleura which 
can further restrict lung function. Therapeutic options for pleural space infections include 
intravenous antibiotiCS, chest tube drainage, intrapleural administration of a fibrinolytiC 
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agent to dissolve fibrous adhesions, thoracotomy to remove fibrinous and infected tissue 
and steroid therapy (Chapman 2004). The theoretical basis for using steroids in patients 
with TPE is that they suppress the inflammatory response, which is believed to be 
responsible for the condition. Prednisone or prednisolone is recommended at a daily 
dose of about 1 mg/kg gradually reducing after one to two weeks with a total treatment 
course sometimes being as long as three months (lemaistre 1951; Mathur 1960; 
Morehead 1998; Blumberg 2003). 
1.3 Debates 
Studies of adjunctive steroids for the treatment of TPE show conflicting results. Non-
randomised studies done in the pre-HIV era found that steroids led to more rapid 
resolution of the effusion and reduced likelihood of residual pleural thickening and pleural 
adhesions (Menon 1964; Singh 1965). Recently, an observational study of HIV positive 
participants with TPE found that compared with those not treated, prednisolone was 
associated with faster resolution of lymphadenopathy, [relative risk (RR) = 2.28,95% CI = 
1.27; 4.10] and cough [RR = 2.15, (1.21; 3.84)] (Elliott 1992). 
In contrast, a critical appraisal of published studies demonstrated beneficial effects of 
steroids on acute symptoms, but found no benefit for chronic endpoints such as fibrosis, 
irrespective of dose (Dooley 1997). The authors noted that many of the stUdies however, 
lacked rigour and clinical correlations. Furthermore, a previous Cochrane review 
encompassing three randomised trials (total participants n=236) concluded that there was 
insufficient evidence for the effectiveness of adjunctive steroids verses placebo on 
mortality or morbidity as measured by incidence of pleural adhesions, RR = 0.30, [95% 
CI: 0.03;2.66]; residual pleural thickening at the end of treatment, RR = 0.75, 
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[0.44;1.28]; residual fluid at the end of treatments, RR = 0.29 [0.06;1.35] and acute 
clinical symptoms, RR = 0.07 [0.00;1.16]. No HIV-related data were available at the time. 
In addition to the uncertainty about benefits of steroid therapy there is also concem about 
potential risks. In immunocompromised patients, such as those infected with HIV, 
steroids may further constrain the immune system leading to an increased frequency of 
opportunistic infections and tumours such as Kaposi sarcoma, a vascular tumour 
accompanied by numerous unconnected lesions of the skin which is thought to be 
associated with human herpes virus-8 infection (Ensoli 2001). More generally, adverse 
effects of steroids such as fluid retention and gastrointestinal disturbances have also 
been documented in people with TB (Anonymous 1983). 
1.4 Aim of study 
The aim of the study was to appraise the existing evidence on the benefits and harms of 
steroids regardless of individuals' H IV status. The study hypothesis was that in patients 
with TB pleurisy, there was no difference in the effects of steroid therapy and placebo on 




To examine the evidence from randomised controlled trials concerning the effects of 
steroids in people with tuberculosis of the pleura. 
2.2 Inclusion criteria for studies in this review 
2.2.1 Types of studies 
Randomised and quasi-randomised trials 1 
2.2.2 Types of participants 
Persons diagnosed with TB pleurisy by chest X-ray (as defined by authors) in addition to 
anyone of the following: pleural biopsy for histology, Ziehl-Neelsen staining and/or 
culture of sputum, pleural fluid or pleural biopsy. 
2.2.3 Types of interventions 
Intervention: Any corticosteroid used in combination with anti-tuberculosis treatment 
(ATT) 
Control: Any of the following in combination with ATT: no treatment, placebo, other 
active treatment 
1 A trial using a quasi-random method, such as alternation, for the allocation of participants 
4 
2.2.4 Types of outcome measures 
PRIMARY 
• Mortality from any cause 
• Improvement in respiratory function 
SECONDARY 
• Reabsorption of pleural effusion (as defined by authors) 
• Presence of pleural thickening 
• Improvement in clinical symptoms and signs 
• Adverse events due to treatment 
• HIV-associated events 
2.3 Search strategy for identification of studies 
An attempt was made to identify all relevant studies regardless of language or publication 
status (published, unpublished, in press, and in progress). 
The following search terms were used for all trial registers and databases (For detailed 







in conjunction with 'tuberculosis or TB'. 
5 
Databases searched: 
a. The Cochrane Infectious Diseases Group specialised trials register for relevant trials 
(up to October 2003). Full details of the Cochrane Infectious Diseases Group methods 
and the journals hand searched are published in The Cochrane Library in the section on 
Collaborative Review Groups. 
b. The Cochrane Central Register of Controlled Trials (CENTRAL), published in The 
Cochrane Ubrary issue 4, 2003. 
c. Electronic databases searched using the above search terms in combination with the 
search strategy developed by The Cochrane Collaboration and detailed in the Cochrane 
Reviewers' Handbook (Clarke 2003): 
(1) MEDLINE (January 1966 to October 2003); 
(2) EMBASE (January 1980 to October 2003); 
(3) LILACS (La Literatura Latinoamericana y del Caribe de Informacion en Ciencias 
de Salud) www.bireme.br; accessed October 2003; 
(4) U.S. National Institutes of Health. ClinicalTrials.gov <http://www.clinicaltrials.gov> 
accessed October 2003; and 
(5) Current Controlled Trials. <http://www.controlled-trials.com/> accessed October 
2003. 
We also scanned references from review articles and primary studies and contacted 
experts in the field of tuberculosis to identify any additional unpublished and ongoing 
trials. 
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2.4 Study selection 
The results of the search were screened to select potentially relevant studies. Two 
reviewers (ME, author and JV. supervisor) independently applied eligibility criteria, based 
on the study design. type of participant and interventions assessed. Differences in 
opinion were resolved through discussion. Where the abstracts were unclear or if there 
was any other reason for uncertainty, we obtained the full article before making a 
decision on study eligibility. When abstracts were not available in English we obtained 
the assistance of translators. 
2.5 Assessment of methodological quality of trials 
The quality of included trials was independently assessed using the following criteria: 
(1) Generation of allocation sequence: judged as 'adequate' if methods such as table of 
random numbers. computer generated random numbers, or coin tossing were used. 
(2) Concealment of allocation: judged as 'adequate' if methods such as central 
randomisation, sequentially numbered, sealed, opaque envelopes were used. 
(3) Blinding: we reported whether investigators, participants, or assessors were blinded. 
(4) Completeness to follow up: we recorded the percentage of randomised participants 
included in the analysis in each study. 
2.6 Data extraction 
Using a specially designed data extraction form (see Appendix 1), the following 
information was extracted for each trial with JV independently cross checking the data: 
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(1) Trial characteristics 
• Method of randomisation 
• Allocation concealment 
• Blinding 
• Type, frequency and duration of follow up 
• Duration of trial 
• Diagnostic criteria used, noting specifically whether participants were culture 
negative or positive 
• Morbidity and mortality outcomes 
• Adverse effects 
(2) Intervention characteristics 
• Type of treatment 
• Dose of treatment 
• Administration route of treatment 




• HIV status 




Data were analysed using Review Manager (Version 4.2). We pooled estimates of effect 
using relative risks for binary data. We assessed heterogeneity by visually examining the 
forest plot and by the statistical Chi-square test for heterogeneity using a 10% level of 
significance. In the absence of homogeneity of treatment effects, we planned to use a 
random effects model. We planned to investigate clinical heterogeneity based on 
participants' HIV status. We also planned to conduct a sensitivity analysis based on 
study quality using adequacy of allocation of concealment as an indicator of the quality. 
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3. RESULTS 
3.1 Description of studies 
Forty-two studies were assessed of which 1 unpublished and 16 published trials were 
identified for possible inclusion into the review. 
3.1.1 Included Trials 
Four trials with 433 participants (Lee 1988, Galarza 1995, Wyser 1996, Elliott 2003) met 
our inclusion criteria. Included trials were conducted in Taiwan (Lee 1988), Spain 
(Galarza 1995), South Africa (yVyser 1996) and Uganda (Elliott 2003) with sample sizes 
being 45, 117, 74 and 197 respectively. All studies included participants of both sexes. 
Participants were adults except in one study (Galarza 1995) which included children from 
11 years of age. One trial (Elliott 2003) comprised only HIV-positive participants, two 
(Galarza 1995, Wyser 1996) excluded HIV positive partiCipants, while in the remaining 
study (Lee 1988), HIV status was not determined. All participants with pleural effusion 
had TB confirmed by a laboratory diagnosis except for Galarza (1995), where only 63% 
of participants had a confirmatory pathological or micro-biological diagnosis, Trials 
considered in this review are described in 'Table 1: Characteristics of included studies'. 
Three trials were published in languages other than English and are awaiting translation 
and further assessment. The reasons for excluding studies, initially considered relevant, 
are provided in Table 2: Characteristics of excluded stUdies', 
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Table 1: Characteristics of included studies 
Study Methods Participants Interventions 
Elliott Computer generated Men and women. mean age Experimental = A TT plus 
2003 random numbers. 34 years. admitted to a single prednisolone. 
Concealment hospital in Uganda with Control = ATT plus placebo. 
adequate. Placebo- tuberculous pleural effusion. ATT consisted of: INH 5mg1kg/d (max. 
controlled. 1.5% Diagnosis confirmed by 300mg/d). Rifampicin 10mg1kg/d (max 
excluded from microbiological culture and/or 600 rng/d), pyrazinamide 18-26 
analysis. histopathology on pleural mglkg/d. ethambutol 14-21 mg/kg/d • 
biopsy. pleural fluid or sputum. for 2 months followed by 4 months of 
INH and Rifampicin. Prednisolone was 
given as a single oral dose of SOmg/d 
for 14 days, 40mg/d for 14 days, 
25mg/d for 14 days, 15mg/d for 14 
days. 
Galarza Random allocation. Men and women aged 11 to Experimental = A TT plus prednisone 
1995 Concealment unclear. 53 years admitted to a single Control = A TT plus placebo 
Placebo-controlled. hospital in Spain with A TT consisted of: INH 5mglkg/d (max. 
No loss to follow up. tuberculous pleural effusion. 300mg/d) and Rifampicin 1 Omglkg/d 
Intention to treat Definite microbiological or (max 600 mg/d) once daily as a 
analysis done. None pathological diagnosis in 63% combination tablet for 6 months. 
excluded from of patients. Prednisone was given as a single oral 
analysis. dose of 1mg/kg/d for 15 days tapering 
off over the next 15 days 
Lee Random allocation. Men and women aged 18 to Experimental = A TT plus prednisolone 
1988 Concealment unclear. 45 years admitted to a single Control = ATT plus placebo 
Placebo-controlled. hospital in Taiwan with A TT consisted of: Ethambutol 
11 % excluded from tuberculous pleural effusion. 20mglkg/d for 3 months; INH 300mg/d 
analysis. Diagnosis confirmed on and Rifampicin 450mg/d for 9-12 
pleural biopsy reported as months. 
"tuberculosis or chronic Prednisolone was given as an oral 
granulomatous inflammation". dose of 0.75mglkg/d initially and 
tapered gradually over 2-3 months 
once radiological improvement was 
seen. 
Wyser Random allocation. Men and women. mean age Experimental = A TT plus prednisone 
1996 Concealment unclear. 33 years admitted to a Single Control = A TT plus placebo. 
Placebo-contro"ed. hospital in South Africa with ATT consisted of Rifampicin 
5% excluded from tuberculous pleurisy. 10mg/kg/d, INH 8mglkg/d, and 
analysis. Diagnosis confirmed on Pyrazinamide 25mg/kg/d as a fixed 
pleural biopsy showing combination tablet (Rifater) and 
caseating granulomata +/- pyridoxine 25mg/kg/d for 6 months 
acid-fast bacilli on histology Prednisone was given as an oral dose 
and/or positive TB culture. of 0.75mglkg/d for 2-4 weeks. After 
clinical and radiological improvement 
the dose was tapered by 5mg/d over 2 
weeks. 
A IT = Antituberculous Therapy 
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Table 1: Characteristics of included studies (Cont') 
Study Outcomes Notes Allocation 
concealment 
Elliott 1. All cause mortality 1. HIV-negatives excluded A 
2003 2. Adverse effects related to steroid use 2. Pleural aspiration and, if 
3. Resolution of tuberculosis possible, biopsy for all 
4. HIV-related events patients on admission. 
3. Three patients (1.5%) 
excluded from analysis: 1 
died from DVT and 
pulmonary embolism and 
reasons are not given for the 
rest. 
Galarza 1. Time to normal temperature 1. Before discharge pleural B 
1995 2. Lung function assessed by FVC at end fluid was drained to one third 
of treatment of hemithorax in all patients 
3. Pleural thickening at baseline and at 1, 2. HIV positives excluded. 
6 and 12 months after start of treatment 
4. Rate of reabsorption of pleural fluid on 
Chest X Ray at baseline and at 1, 6 and 
12 months after start of treatment 
5. Adverse effects 
Lee 1. Resolution of clinical symptoms and 1. Diagnostic thoracocentesis B 
1988 signs «5OmI) on first day for all 
2. Rate of reabsorption of pleural fluid on patients 
Chest X Ray 2. Five patients (11 %) 
3. Pleural adhesions and thickening excluded from analysis: 1 
4. Adverse effects developed renal cell 
carcinoma and 4 did not 
return for follow-up 
3. Duration of follow-up not 
stated. 
4. HIV status of patients not 
stated. 
Wyser 1. Resolution of symptoms. Dyspnoea, 1. HIV positives excluded B 
1996 cough, night sweats, tiredness, appetite, 2. Thoracoscopy, 
pleuritic chest pain and general well-being bronchoscopy, and complete 
were each graded from 0 to 100 using a aspiration of pleural fluid for 
visual analogue scale and combined index all patients on admission. 
with a maximum score of 700 was 3. Four patients (5%) 
calculated. excluded from analysis: 1 
2. Lung function at end of treatment as developed oesophageal 
assessed by TLC and FVC carcinoma and 3 were not 
3. Recurrence of effusion compliant 
4. Residual pleural thickening at 24 weeks 
5. Adverse effects. 
Allocation concealment: A: Adequate; B: Unclear; C: Inadequate; D: Not used 
(See Appendix 2 for further explanation) 
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Reason for exclusion 
No randomisation or pseudorandomisation. 
Participants did not have pleurisy - cases of pulmonary TB 
Case series 
Review 
Numbers of patients in each arm not clearly stated. 
No randomisation or pseudorandomisation. 
Diagnosis of tuberculosis not confirmed. 
No randomisation or pseudorandomisation. 
Letter referring to Included trial (Galarza 1995). 
No randomisation or pseudorandomisation. 
No randomisation or pseudorandomisation. 
No randomisation or pseudorandomisation. 
No randomisation or pseudorandomisation. 
No randomisation or pseudorandomisation. 
No randomisation or pseudorandomisation. 
No randomisation or pseudorandomisation. 
No randomisation or pseudorandomisation. 
13 
3.1.2 Interventions 
Pleural fluid was aspirated prior to randomisation in all but one study (Galarza 1995) 
where aspiration was conducted prior to patient discharge. In all cases oral steroids or 
placebo were administered in addition to standard anti-tuberculous therapy (Arr). 
Prednisolone was administered in two trials (Lee 1988, Elliott 2003) at a daily dose of 
approximately 0.75mg/kg/day for two weeks while prednisone was administered in the 
remaining stUdies (Galarza 1995, Wyser 1996) at a dose ranging from 0.75 to 1.0 
mglkg/day for two weeks. In all cases, the dose was tapered off over a further two-week 
period. Rifampicin and isoniazid were included in the A IT regimen in all studies. 
3.1.3 Follow-up 
The period of follow-up varied across studies, ranging from 24 weeks (Wyser 1996) to 46 
months (Galarza 1995). Lee et al (1988) did not mention how long participants had been 
followed, but reported at least one outcome 395 days post-treatment. 
3.1.4 Outcome measures 
The outcome measures reported were mortality, clinical improvement during treatment. 
reabsorption of pleural effusion, pleural thickening measured by chest X-ray (CXR). 
respiratory function, improvement in clinical symptoms and signs at the end of treatment, 
adverse effects and HIV-associated complications. 
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3.2 Methodological quality of included studies 
3.2.1 Generation of allocation sequence 
All trials were reported as randomised. Elliott (2003) explicitly stated that random 
numbers were computer-generated, which we considered as adequate. The other trials 
did not indicate how the sequence was generated. 
3.2.2 Allocation concealment 
One trial gave a detailed report of this aspect of study quality, which we considered to be 
an adequate method; briefly, prednisolone and matching placebo tablets were packaged 
in identical sequentially numbered plastic bags labelled with the randomisation code by 2 
people unrelated to the study (Elliott 2003). The rest did not provide sufficient information 
to assess this aspect of study quality. 
3.2.3 Blinding 
All studies were described as double-blind and placebo-controlled. Wyser (1996) and 
Elliott (2003) specifically mentioned that those assessing outcomes had been blinded. 
3.2.4 Inclusion of all randomised participants 
Loss to follow up either did not occur (Galarza 1995) or was small: 11% (Lee 1988), 5% 
(Wyser 1996) and 1.5% (Elliott 2003). 
Only Galarza (1995) undertook an intention-to-treat analysis. 
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3.3 Analysis 
3.3.1 Mortality from any cause 
Only one trial assessed the risk of death, finding no statistically significant difference 
between steroids and placebo in the reduction of mortality (Elliott 2003 with 194 
participants: relative risk (RR) = 0.92, 95% confidence interval (CI) 0.65 to 1.32), 
(Figure 1). 
Figure 1: Mortality from any cause. 
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3.3.2 Improvement in respiratory function 
Two trials (Galarza 1995 and Wyser 1996) evaluated improvement in respiratory fundion 
finding no difference between steroid and control groups. In Galarza (1995) mean forced 
vital capacity (FVC) was 95% in both the treatment and control groups at the end of 
treatment. 
Wyser (1996) reported no significant difference in the degree of improvement in 
pulmonary function between the prednisone and placebo groups, (Total Lung Capacity: 
p=0.39; FVC: p=0.65) up to six months. 
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3.3.3 Residual pleural effuSion 
Steroids reduced residual fluid at 4 weeks (2 trials, Galarza 1995, Elliott 2003 with 311 
participants: RR = 0.67, 95% CI 0.50 to 0.90) as well as at 8 weeks (2 trials, Lee 1988, 
Elliott 2003, with 234 participants: RR = 0.53, 95% CI 0.37 to 0.77), (Figure 2). No 
statistical heterogeneity was detected for either of these outcomes. In the remaining 
study (Wyser 1996), complete drainage of pleural fluid was undertaken on admission and 
effusions did not recur in either group during the course of the study. 
Figure 2: Residual pleural effusion. 
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3.3.4 Presence of pleural thickening and pleural adhesions 
A reduction in the risks of both residual pleural thickening (3 trials, Lee 1988, Galarza 
1995, Wyser 1996, with 227 participants: RR = 0.76, 95% CI 0.48 to 1.21) and pleural 
adhesions 1 trial Lee (1998) with 45 participants RR = 0.30,95% CI 0.03 to 2.66) were 
observed but neither of these findings were statistically significant, (Figure 3). 
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Figure 3: Presence of pleural thickening and pleural adhesions . 
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3.3.5 Improvement in clinical symptoms and signs 
Fever, chest pain and dyspnoea were more likely to be resolved by 7 days post-treatment 
in one study (Lee 1988) in participants on steroids compared to placebo (RR = 0.06,95% 
CI 0.00 to 0.99), (Figure 4). In the same study, steroids reduced the mean number of 
days to disappearance of acute symptoms (p<0.05). All participants, however, were 
asymptomatic within 14 days. Wyser (1996) reported no differences in the degree of 
improvement in symptoms (individual or combined Visual Analogue Scores) or in mean 
weight gain at regular follow-up evaluations over a 24 week period. 
Figure 4: Improvement in clinical symptoms and signs 
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3.3.6 Adverse events due to treatment 
Overall, more people in the steroid group experienced adverse effects leading to the 
discontinuation of treatment (3 trials, Lee 1988, Wyser 1996, Elliott 2003 with 304 
participants: RR = 2.67,95% C11.03 to 6.96), (Figure 5). In Elliott (2003), 9 of 97 
participants in the treatment group and 2 of 97 participants in the placebo group required 
stoppage of treatment due to hyperglycaemia, hypertension, herpes zoster or candida 
infections. Epigastric pain was reported by Wyser (1996) in 4 of 34 participants on 
steroid therapy and 3 of 36 on placebo and by Lee (1988) in 1 of 21 participants on 
steroids and none in the placebo group. The same participant in Lee (1988) developed a 
'moon' face and lower limb oedema. Galarza found no adverse effects. 
Figure 5: Adverse events due to treatment 
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3.3.7 HIV-associated events 
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One trial comprising only H IV-positive participants reported a trend towards an increase 
in the incidence of Kaposi's sarcoma in participants receiving steroids (Elliott 2003, with 
194 participants: RR = 13.00, 95% CI 0.74 to 227.63), (Figure 6). This trial found no 
evidence of an effect of steroids on HIV-associated infections including Cryptococcal 
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meningitidis, esophageal candidiasis, Herpes simplex, Herpes zoster, oral thrush and 
gastroenteritis. 
Figure 6: HIV-associated events 
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4. DISCUSSION 
The evidence base on the effects of corticosteroids administered to people with 
tuberculous pleurisy remains small, with only four trials evaluating 433 participants. 
Only the trial in people infected with H IV evaluated mortality. Due to the small number of 
events in this study the confidence interval around the effect estimate is wide thus 
precluding firm conclusions about the effect of steroids on death. The other primary 
outcome we aimed to assess was improvement in respiratory function. Neither of the 
two trials focussing on this endpoint provided evidence for benefit of steroids; there was 
insufficient information to allow us perform a meta-analysis. 
Compared to placebo, steroids appear to hasten the resorption of pleural fluid with the 
pooled results from two trials showing statistically significant reductions of residual fluid at 
four and eight weeks. The clinical importance of this finding is, however, difficult to 
interpret. One trial found fewer symptoms at seven days as well as a reduction of the 
mean number of days to disappearance of symptoms in the steroid arm, while the other 
found no difference in symptom severity between the comparison groups. There is no 
evidence that steroids reduce pleural thickening at the end of treatment either from the 
combined results based on three trials or the biggest of the trials with a relative risk of 
one. 
Adverse events due to treatment were infrequent and mostly mild. There is theoretical 
concern that corticosteroid-induced immunosuppression may increase the risk of 
opportunistic infections in HIV-infected participants (Lionakis 2003). Thus the episodes 
of herpes zoster and esophageal candidiasis, leading to cessation of treatment in Elliott 
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2003 are noteworthy. There were, however, no statistically significant differences 
between steroid and placebo arms for any of the opportunistic infections assessed in this 
trial. In the same trial the risk of Kaposi sarcoma was found to be substantially higher in 
the steroid group (RR = 13, 95% CI 0.74 to 227.63). This is a potentially important 
finding which requires confirmation in future trials. 
In interpreting the above findings a number of factors need to be kept in mind. Firstly, all 
4 trials included in this review were small (sample sizes ranged from 45 to 197), thus 
increasing the likelihood of both type I and type II error. For example, the single study 
reporting on mortality will not have been Sufficiently powered to assess this outcome. It 
can be shown that 356 patients per study arm would be required to demonstrate a 10% 
reduction in mortality from the baseline of 39/97. Secondly, while the methodological 
quality of the available studies seems reasonably sound, we did not have sufficient 
information to assess the completeness of allocation concealment in three of the four 
trials, a factor known to have a substantial influence on internal validity. A third issue 
concerns the diagnosis of TPE which was not confirmed in one-third of participants in the 
Galarza 1995 trial; there is no indication as to the distribution of unconfirmed diagnoses 
in the study arms. Fourthly, the optimal dose of adjunctive steroids is not known. 
Rifampicin induces the liver metabolism of corticosteroids, thus increasing their plasma 
clearance (McAllister 1983). It has been suggested that higher doses be used to 
compensate for the reduced availability of steroids to the tissues (Commerford 1991). 
Furthermore, the choice of steroid varied across the studies: two trials used prednisolone 
and the other two, prednisone. Prednisone is a pro-drug that requires metabolism in the 
liver to prednisolone, the active component. 
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Finally, three of the trials were carried out in the pre-HIV era and thus the generalisability 
of the current evidence to most participants with TPE in low and middle income countries 
who are coinfected with HIV is limited. 
5. CONCLUSIONS 
5.1 Implications for practice 
While evidence from published trials suggests that adjunctive steroid therapy is beneficial 
for reducing residual pleural fluid, there is currently insufficient data to support evidence-
based recommendations regarding the use of steroids on risk of death or improvement in 
lung function in patients with tuberculous pleural effusion, regardless of HIV status. There 
is some cause for concern that steroids may increase the risk of Kaposi sarcoma in 
patients infected with HIV. 
5.2 Implications for research 
Randomised controlled trials with sufficient statistical power to evaluate the effects of 
steroids on mortality and key morbidity outcomes are needed. Careful attention should 
be given to adverse effects particular in patients who are HIV positive. 
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7. APPENDIX 
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7.2 Data extraction form 
Data Extraction Form 
10 NUMBER: 
Authors: 






Study design and conduct: 





Date trial was initiated: 
Total duration of trial (treatment plus follow-up): 
Duration of follow-up: 
Type of follow-up: 
Frequency of follow-up: 
Loss to follow-UD' 
Total 
Total number randomised 
Number available to follow-
up 
Loss to follow-up 







% of total number randomised included in analysis? ______ _ 
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PARTICIPANTS: 
Country and setting: 
Numbers of persons in trial: 
Total Intervention Control 
I Number 
1% of total 100% 
Gender of persons in trial: 
Total Intervention Control 
N % N % N % 
Male 
Female 
TOTAL 100% 100% 100% 
Age of persons in trial: 
Total Intervention Control 
Mean age 
Age range 
N % N % N % 
=< 13 year 
> 13 year 
Diagnosis of TB pleural effusion: I-y,..;...e,..;...s...._--+-=N...:...o=----I--=U:.:.nc.:...::..::.-::le:..:.:a:::.-r ~ 
Chest X-Ray 
Pleural biopsy for histology 
Positive Ziel-Neelsen stain 














Outcomes and Results: 
Intervention Control Significant Not reported 
Death 
Improvement in respiratory function 
Improvement in clinical symptoms 
Reabsorption of pleural effusion 
Worsening of parenchymal disease 
(pos MFB sputum at end of 
treatment) 











I HIV-positive participants 
If "yes": 
Intervention Controls 




Information outstanding, to be requested: 
Comments on ethics of study: 
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7.3 Allocation concealment (RevMan Manuaf) 
Adequate methods of allocation concealment include: 
• centralised randomisation schemes; 
• randomisation schemes controlled by a pharmacy; 
• numbered or coded containers in which capsules from identical-looking, numbered 
bottles are administered sequentially; 
• on-site computer systems, where allocations are in a locked unreadable file; 
• sequentially numbered opaque, sealed envelopes. 
Rated as A: Adequate; B: Unclear; C: Inadequate; D: Not used 
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